MedTrace Logo

Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

NCT02910557 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 187

Last updated 2026-02-05

No results posted yet for this study

Summary

A postmarketing Cohort study of Melanoma patients treated with IMLYGIC (Talimogene Laherparepvec) in clinical Practice to Characterize the risk of herpetic infection with detection of Talimogene Laherparepvec DNA among patients, close contacts, and health care providers; and long term safety in treated patients for up to 5 years after the first IMLYGIC dose.

Conditions

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-10
Primary Completion
2026-01-30
Completion
2026-01-30

Countries

  • United States
  • Austria
  • Israel
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02910557 on ClinicalTrials.gov